|
CANAVESE G.-DOZIN B.-VECCHIO C.-TOMEI D.-VILLA G.-CARLI F.-DEL
MASTRO L.-LEVAGGI A.-ROSSELLO C.-SPINACI S.-BRUZZI P.-CATTURICH A.
Accuracy of sentinel lymph node biopsy after neo adjuvant
chemotherapy in patients with locally advanced breast cancer and
clinically positive axillary nodes.
Eur. J. Surg. Oncol. 37:688/694, 2011
PubMed Abstract
CHAPMAN P.B.-HAUSCHILD A.-ROBERT C.-HAANEN J.-ASCIERTO P.-LARKIN
J.-DUMMER R.-GARBE C.-TESTORI A.-MAIO M.-HOGG D.-LORIGAN P.-LEBBE
C.-JOUARY T.-SCHADENDORF D.-RIBAS A.-O'DAY S.-SOSMAN J.-KIRKWOOD
J.-EGGERMONT A.-DRENO B.-NOLOP K.-LI J.-NELSON B.-HOU J.-LEE R.-
FLAHERTY K.-MCARTHUR A.-BRIM/3 Study Group-QUEIROLO P.
Improved survival with vemurafenib in melanoma with BRAF V600E
mutation.
N. Engl. J. Med. 364(26):2507/2516, 2011
PubMed Abstract
DEL MASTRO L.-GIRAUDI S.-LEVAGGI A.-PRONZATO P.
Medical approaches to preservation of fertility in female cancer
patients.
Expert. Opin. Pharmacother. 12(3):387/396, 2011
PubMed Abstract
LAMBERTINI M.-PRONZATO P.-GIRAUDI S.-LEVAGGI A.-BIGHIN C.-DEL
MASTRO L.
Letrozole withdrawal response in locally advanced breast cancer.
Letter.
Ann. Oncol. 22:1927/1928, 2011
PubMed Abstract
MAIO M.-NICOLAY H.-ASCIERTO P.-BELARDELLI F.-CAMERINI R.-COLOMBO
M.P.-QUEIROLO P.-RIDOLFI R.-RUSSO V.-FONSATTI E.-NIBIT-PARMIANI G.-
FERRINI S.
Eighth annual meeting of the Italian network for tumor biotherapy
(NIBIT), Siena, October 7/9, 2010.
Cancer Immunol. Immunother. 60:901/907, 2011
PubMed Abstract
BELLO C.-CEA M.-DAL BELLO G.-GARUTI A.-ROCCO I.-CIRMENA G.-MORAN
E.-NAHIMANA A.-DUCHOSAL M.-FRUSCIONE F.-PRONZATO P.-GROSSI F.-
PATRONE F.-BALLESTRERO A.-DUPUIS M.-SORDAT B.-NENCIONI A.-VOGEL P.
Novel 2/[(benzylamino)methyl]pyrrolidine/3,4/diol derivatives as
alpha/mannosidase inhibitors and with antitumor activities against
hematological and solid malignancies.
Bioorg. Med. Chem. 18:3320/3334, 2010
PubMed Abstract
BIGHIN C.-DEL MASTRO L.-CANAVESE G.-CARLI F.-TAVEGGIA P.-LEVAGGI
A.-GIRAUDI S.-PRONZATO P.
Use in current clinical practice of 70 gene signature in early
breast cancer. Letter.
Int. J. Cancer 127:2736/2737, 2010
PubMed Abstract
BIGHIN C.-LUNARDI G.-DEL MASTRO L.-MARRONI P.-TAVEGGIA P.-LEVAGGI
A.-GIRAUDI S.-PRONZATO P.
Estrone sulphate, FSH, and testosterone levels in two male breast
cancer patients treated with aromatase inhibitors.
Oncologist 15:1270/1272, 2010
PubMed Abstract
BISIO A.-NASTI S.-JORDAN J.-GARGIULO S.-PASTORINO L.-PROVENZANI A.-
QUATTRONE A.-QUEIROLO P.-BIANCHI SCARRA' G.-GHIORZO P.-INGA A.
Functional analysis of CDKN2A/p16INK4a 5'/UTR variants
predisposing to melanoma.
Hum. Mol. Genet. 19(8):1479/1491, 2010
PubMed Abstract
BORCARD F.-BAUD M.-BELLO C.-DAL BELLO G.-GROSSI F.-PRONZATO P.-CEA
M.-NENCIONI A.-VOGEL P.
Synthesis of new oxathiazinane dioxides and their in vitro cancer
cell growth inhibitory activity.
Bioorg. Med. Chem. Lett. 20:5353/5356, 2010
PubMed Abstract
CORREA C.-MCGALE P.-TAYLOR C.-WANG Y.-CLARKE M.-DAVIES C.-PETO R.-
BIJKER N.-SOLIN L.-DARBY S.-Early Breast Cancer Trialists'
Collaborative Group (EBCTCG)-BOCCARDO F.-RUBAGOTTI A.-BRUZZI P.-
DEL MASTRO L.-PRONZATO P.-SERTOLI M.R.-VENTURINI M.
Overview of the randomized trials of radiotherapy in ductal
carcinoma in situ of the breast.
J. Natl. Cancer Inst. Monogr. 2010(41):162/177, 2010
PubMed Abstract
DEL MASTRO L.-BIGHIN C.-BINI G.-GIRAUDI S.-TAVEGGIA P.-LEVAGGI A.-
CANAVESE G.-RESCINITO G.-PRONZATO P.
Trastuzumab before breast surgery: is concurrent administration
with anthracycline containing chemotherapy necessary? Letter.
Ann. Oncol. 21(6):1376/1377, 2010
PubMed Abstract
DEL MASTRO L.-LEVAGGI A.-GIRAUDI S.-PRONZATO P.
Luteinising hormone releasing hormone agonists (LH/RHa) in
premenopausal early breast cancer patients: current role and
future perspectives.
Cancer Treat. Rev. 37:208/211, 2011 - Epub Aug 17, 2010
PubMed Abstract
DEL VECCHIO M.-MORTARINI R.-CANOVA S.-DI GUARDO L.-PIMPINELLI N.-
SERTOLI M.R.-BEDOGNETTI D.-QUEIROLO P.-MOROSINI P.-PERRONE T.-
BAJETTA E.-ANICHINI A.
Bevacizumab plus fotemustine as first line treatment in metastatic
melanoma patients: clinical activity and modulation of
angiogenesis and lymphangiogenesis factors.
Clin. Cancer Res. 16(23):5862/5872, 2010
PubMed Abstract
MAIO M.-NICOLAY H.-ASCIERTO P.-BELARDELLI F.-CAMERINI R.-COLOMBO
Ma.-QUEIROLO P.-RIDOLFI R.-RUSSO V.-FONSATTI E.-PARMIANI G.-NIBIT
Seventh annual meeting of the Italian Network for Tumor Biotherapy
(NIBIT), Siena, 1/3 October 2009.
Cancer Immunol. Immunother. 59:1895/1901, 2010
PubMed Abstract
MASI G.-VASILE E.-LOUPAKIS F.-CUPINI S.-FORNARO L.-BALDI G.-
SALVATORE L.-CREMOLINI C.-STASI I.-BRUNETTI I.-FABBRI M.-PUGLISI
M.-TRENTA P.-GRANETTO C.-CHIARA S.-FIORETTO L.-ALLEGRINI G.-CRINO'
L.-ANDREUCCETTI M.-FALCONE A.
Randomized trial of two induction chemotherapy regimens in
metastatic colorectal cancer: an updated analysis.
J. Natl. Cancer Inst. 103:21/30, 2011 - Epub Dec 1, 2010
PubMed Abstract
O'DAY S.-MAIO M.-CHIARION SILENI V.-GAJEWSKI T.-PEHAMBERGER H.-
BONDARENKO I.-QUEIROLO P.-LUNDGREN L.-MIKHAILOV S.-ROMAN L.-
VERSCHRAEGEN C.-HUMPHREY R.-IBRAHIM R.-DE PRIL V.-HOOS A.-WOLCHOK J.
Efficacy and safety of ipilimumab monotherapy in patients with
pretreated advanced melanoma: a multicenter single arm phase II
study.
Ann. Oncol. 21:1712/1717, 2010
PubMed Abstract
PRONZATO P.-CORTESI E.-VAN DER RIJT C.-BOLS A.-MORENO NOGUEIRA J.-
DE OLIVEIRA C.-BARRETT LEE P.-OSTLER P.-ROSSO R.-EPO/INT/47 Study
Group
Epoetin alfa improves anemia and anemia related, patient reported
outcomes in patients with breast cancer receiving myelotoxic
chemotherapy: results of a european, multicenter, randomized,
controlled trial.
Oncologist 15:935/943, 2010
PubMed Abstract
VENTURINI M.-BIGHIN C.-PUGLISI F.-OLMEO N.-AITINI E.-COLUCCI G.-
GARRONE O.-PACCAGNELLA A.-MARINI G.-CRINO' L.-MANSUTTI M.-BACONNET
B.-BARBATO A.-DEL MASTRO L.
A multicentre phase II study of non pegylated liposomal
doxorubicin in combination with trastuzumab and docetaxel as first
line therapy in metastatic breast cancer.
Breast 19:333/338, 2010
PubMed Abstract
2008 Erice Group-CARPANELLI I.-PRONZATO P.
The 2008 Erice statement toward a more humanistic oncology.
J. Ambul. Care Manage. 32:252/258, 2009
PubMed Abstract
BALSAMO M.-SCORDAMAGLIA F.-PIETRA G.-MANZINI C.-CANTONI C.-BOITANO
M.-QUEIROLO P.-VERMI W.-FACCHETTI F.-MORETTA A.-MORETTA L.-MINGARI
M.C.-VITALE M.
Melanoma associated fibroblasts modulate NK cell phenotype and
antitumor cytotoxicity.
Proc. Natl. Acad. Sci. USA 106:20847/20852, 2009
PubMed Abstract
BANELLI B.-CASCIANO I.-DI VINCI A.-GATTESCHI B.-LEVAGGI A.-CARLI
F.-BIGHIN C.-SALVI S.-ALLEMANNI G.-GHIORZO P.-PRONZATO P.-
VENTURINI M.-ROMANI M.-DEL MASTRO L.
Pathological and molecular characteristics distinguishing
contralateral metastatic from new primary breast cancer.
Ann. Oncol. 21:1237/1242, 2010 - Epub Oct 29, 2009
PubMed Abstract
BIG 1/98 Collaborative Group-MOURIDSEN H.-GIOBBIE HURDER A.-
GOLDHIRSCH A.-THURLIMANN B.-PARIDAENS R.-SMITH I.-MAURIAC L.-
FORBES J.-PRICE K.-REGAN M.-GELBER R.-COATES A.-ROSSO R.-DEL
MASTRO L.-BIGHIN C.
Letrozole therapy alone or in sequence with tamoxifen in women
with breast cancer.
N. Engl. J. Med. 361:766/776, 2009
PubMed Abstract
BRUNO W.-GHIORZO P.-BATTISTUZZI L.-ASCIERTO P.-BARILE M.-GARGIULO
S.-GENSINI F.-GLIORI S.-GUIDA M.-LOMBARDO M.-MANOUKIAN S.-MENIN C.-
NASTI S.-ORIGONE P.-PASINI B.-PASTORINO L.-PEISSEL B.-PIZZICHETTA
M.-QUEIROLO P.-RODOLFO M.-ROMANINI A.-SCAINI M.-TESTORI A.-
TIBILETTI M.-TURCHETTI D.-LEACHMAN S.-BIANCHI SCARRA' G.-IMI
(Italian Melanoma Intergroup)
Clinical genetic testing for familial melanoma in Italy: a
cooperative study.
J. Am. Acad. Dermatol. 61:775/782, 2009
PubMed Abstract
CARREGA P.-PEZZINO G.-QUEIROLO P.-BONACCORSI I.-FALCO M.-VITA G.-
PENDE D.-MISEFARI A.-MORETTA A.-MINGARI M.C.-MORETTA L.-FERLAZZO G.
Susceptibility of human melanoma cells to autologous natural
killer (NK) cell killing: HLA related effector mechanisms and role
of unlicensed NK cells.
PLoS One 4:e8132;1/e8132;10, 2009
PubMed Abstract
CASULA M.-ALAIBAC M.-PIZZICHETTA M.-BONO R.-ASCIERTO P.-
STANGANELLI I.-CANZANELLA S.-PALOMBA G.-ZATTRA E.-Italian Melanoma
Intergroup (IMI)-PALMIERI G.-QUEIROLO P.
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an
experience on a large series of Italian cases and controls.
BMC Dermatol. 9:7;1/7;6, 2009
PubMed Abstract
GHIORZO P.-PASTORINO L.-PIZZICHETTA M.-BONO R.-QUEIROLO P.-
TALAMINI R.-ANNESSI G.-BRUNO W.-NASTI S.-GARGIULO S.-BATTISTUZZI
L.-SINI M.-PALMIERI G.-BIANCHI SCARRA' G.-Italian Melanoma
Intergroup
CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Melanoma Res. 19:142/145, 2009
PubMed Abstract
GIOBBIE HURDER A.-PRICE K.-GELBER R.-International Breast Cancer
Study Group BIG 1/98 Collaborative Group-ROSSO R.-DEL MASTRO L.-
BIGHIN C.
Design, conduct, and analyses of Breast International Group (BIG)
1/98: a randomized, double blind, phase III study comparing
letrozole and tamoxifen as adjuvant endocrine therapy for
postmenopausal women with receptor positive, early breast cancer.
Clin. Trials 6:272/287, 2009
PubMed Abstract
GROSSI F.-AITA M.-DEFFERRARI C.-ROSETTI F.-BRIANTI A.-FASOLA G.-
VINANTE O.-PRONZATO P.-PAPPAGALLO G.
Impact of third generation drugs on the activity of first line
chemotherapy in advanced non small cell lung cancer: a meta
analytical approach.
Oncologist 14:497/510, 2009
PubMed Abstract
MAIO M.-NICOLAY H.-ASCIERTO P.-BELARDELLI F.-CAMERINI R.-COLOMBO
Ma.-QUEIROLO P.-RIDOLFI R.-RUSSO V.-FONSATTI E.-PARMIANI G.-NIBIT-
FERRINI S.
Sixth annual meeting of the Italian network for tumor biotherapy
(NIBIT), Siena, 16/18 October 2008.
Cancer Immunol. Immunother. 59:963/969, 2010 - Epub Mar 28, 2009
PubMed Abstract
MORABITO A.-DOZIN B.-SALVI S.-PASCIUCCO G.-BALBI G.-LAURENT S.-
PASTORINO S.-CARLI F.-TRUINI M.-BRUZZI P.-DEL MASTRO L.-PISTILLO
M.P.
Analysis and clinical relevance of human leukocyte antigen class
I, heavy chain, and beta2/microglobulin downregulation in breast
cancer.
Hum. Immunol. 70:492/495, 2009
PubMed Abstract
ORTMANN O.-CUFER T.-DIXON J.-MAASS N.-MARCHETTI P.-PAGANI O.-
PRONZATO P.-SEMIGLAZOV V.-SPANO J.-VRDOLJAK E.-WILDIERS H.
Adjuvant endocrine therapy for perimenopausal women with early
breast cancer.
Breast 18:2/7, 2009
PubMed Abstract
PIETRA G.-MANZINI C.-VITALE M.-BALSAMO M.-OGNIO E.-BOITANO M.-
QUEIROLO P.-MORETTA L.-MINGARI M.C.
Natural killer cells kill human melanoma cells with
characteristics of cancer stem cells.
Int. Immunol. 21:793/801, 2009
PubMed Abstract
RABAGLIO M.-SUN Z.-PRICE K.-CASTIGLIONE GERTSCH M.-HAWLE H.-
THURLIMANN B.-MOURIDSEN H.-CAMPONE M.-FORBES J.-PARIDAENS R.-
COLLEONI M.-PIENKOWSKI T.-NOGARET J.-LANG I.-SMITH I.-GELBER R.-
GOLDHIRSCH A.-COATES A.-BIG 1/98 Collaborative International
Breast Cancer Study Groups-ROSSO R.-DEL MASTRO L.-BIGHIN C.
Bone fractures among postmenopausal patients with endocrine
responsive early breast cancer treated with 5 years of letrozole
or tamoxifen in the BIG 1/98 trial.
Ann. Oncol. 20:1489/1498, 2009
PubMed Abstract
SOBRERO A.-ACKLAND S.-CLARKE S.-PEREZ CARRION R.-CHIARA S.-GAPSKI
J.-MAINWARING P.-LANGER B.-YOUNG S.-AVIRI Trial Investigators
Phase IV study of bevacizumab in combination with infusional
fluorouracil, leucovorin and irinotecan (FOLFIRI) in first line
metastatic colorectal cancer.
Oncology 77:113/119, 2009
PubMed Abstract
SOLARI N.-GIPPONI M.-STELLA M.-QUEIROLO P.-DI SOMMA C.-VILLA G.-
PICCARDO A.-GUALCO M.-CARDINALE F.-CAFIERO F.
Predictive role of preoperative lymphoscintigraphy on the status
of the sentinel lymph node in clinically node negative patients
with cutaneous melanoma.
Melanoma Res. 19:243/251, 2009
PubMed Abstract
SPALLAROSSA P.-ALTIERI P.-PRONZATO P.-ALOI C.-GHIGLIOTTI G.-
BARSOTTI A.-BRUNELLI C.
Sub lethal doses of an anti/erbB2 antibody leads to death by
apoptosis in cardiomyocytes sensitized by low pro senescent doses
of epirubicin: the protective role of dexrazoxane.
J. Pharmacol. Exp. Ther. 332:87/96, 2010 - Epub Oct 19, 2009
PubMed Abstract
VASILE E.-MASI G.-FORNARO L.-CUPINI S.-LOUPAKIS F.-BURSI S.-
PETRINI I.-DI DONATO S.-BRUNETTI I.-RICCI S.-ANTONUZZO A.-CHIARA
S.-AMOROSO D.-ANDREUCCETTI M.-FALCONE A.
A multicenter phase II study of the combination of oxaliplatin,
irinotecan and capecitabine in the first line treatment of
metastatic colorectal cancer.
Br. J. Cancer 100:1720/1724, 2009
PubMed Abstract
AITA M.-FASOLA G.-DEFFERRARI C.-BRIANTI A.-DAL BELLO M.G.-FOLLADOR
A.-SINACCIO G.-PRONZATO P.-GROSSI F.
Targeting the VEGF pathway: antiangiogenic strategies in the
treatment of non small cell lung cancer.
Crit. Rev. Oncol. Hematol. 68:183/196, 2008
PubMed Abstract
BENASSO M.-VIGO V.-BACIGALUPO A.-PONZANELLI A.-MARCENARO M.-CORVO'
R.-MARGARINO G.
A phase II trial of low dose gemcitabine and radiation alternated
to cisplatin and 5/fluorouracil: an active and manageable regimen
for stage IV squamous cell carcinoma of the head and neck.
Radiother. Oncol. 89:44/50, 2008
PubMed Abstract
BENGALA C.-BETTELLI S.-BERTOLINI F.-SALVI S.-CHIARA S.-SONAGLIO C.-
LOSI L.-BIGIANI N.-SARTORI G.-DEALIS C.-MALAVASI N.-D'AMICO R.-
LUPPI G.-GATTESCHI B.-MAIORANA A.-CONTE P.
Epidermal growth factor receptor gene copy number, K/ras mutation
and pathological response to preoperative cetuximab, 5/FU and
radiation therapy in locally advanced rectal cancer.
Ann. Oncol. 20:469/474, 2009 - Epub Dec 18, 2008
PubMed Abstract
BERTOLINI F.-CHIARA S.-BENGALA C.-ANTOGNONI P.-DEALIS C.-ZIRONI S.-
MALAVASI N.-SCOLARO T.-DEPENNI R.-JOVIC G.-SONAGLIO C.-ROSSI A.-
LUPPI G.-CONTE P.F.
Neoadjuvant treatment with single agent cetuximab followed by
5/FU, cetuximab, and pelvic radiotherapy: a phase II study in
locally advanced rectal cancer.
Int. J. Radiat. Oncol. Biol. Phys. 73:466/472, 2009 - Epub Nov 10, 2008
PubMed Abstract
CAZZANIGA M.-PRONZATO P.-MUSTACCHI G.-DE MATTEIS A.-DI COSTANZO F.-
RULLI E.-FLORIANI I.
The anthracyclines and the clinical practice: do all breast cancer
patients benefit? Results from the NORA study. Letter.
Ann. Oncol. 19:1811/1812, 2008
PubMed Abstract
EGGERMONT A.-SUCIU S.-SANTINAMI M.-TESTORI A.-KRUIT W.-MARSDEN J.-
PUNT C.-SALES F.-GORE M.-MacKIE R.-KUSIC Z.-DUMMER R.-HAUSCHILD A.-
MUSAT E.-SPATZ A.-KEILHOLZ U.-EORTC Melanoma Group-SERTOLI M.R.-
QUEIROLO P.
Adjuvant therapy with pegylated interferon alfa/2b versus
observation alone in resected stage III melanoma: final results of
EORTC 18991, a randomised phase III trial.
Lancet 372:117/126, 2008
PubMed Abstract
FORNARO L.-MASI G.-BURSI S.-LOUPAKIS F.-VASILE E.-ANTONUZZO A.-
CHIARA S.-PFANNER E.-DI PAOLO A.-BOCCI G.-DEL TACCA M.-FALCONE A.
A dose finding and pharmacokinetic study of capecitabine in
combination with oxaliplatin and irinotecan in metastatic
colorectal cancer.
Cancer Chemother. Pharmacol. 63:965/969, 2009 - Epub Oct 7, 2008
PubMed Abstract
GENNARI A.-PRONZATO P.
New understanding of the role of anthracyclines in early stage
breast cancer: patient selection considerations.
Clin. Breast Cancer 8(Suppl 4):S179/S183, 2008
PubMed Abstract
GUARNERI V.-FRASSOLDATI A.-BRUZZI P.-D'AMICO R.-BELFIGLIO M.-
MOLINO A.-BERTETTO O.-CASCINU S.-COGNETTI F.-DI LEO A.-PRONZATO P.-
CRINO' L.-AGOSTARA B.-CONTE P.
Multicentric, randomized phase III trial of two different adjuvant
chemotherapy regimens plus three versus twelve months of
trastuzumab in patients with HER/2 positive breast cancer
(Short/HER trial; NCT00629278).
Clin. Breast Cancer 8:453/456, 2008
PubMed Abstract
MAIO M.-NICOLAY H.-ASCIERTO P.-BELARDELLI F.-CAMERINI R.-COLOMBO M.-QUEIROLO P.-RIDOLFI
R.-RUSSO V.-ANZALONE L.-FONSATTI E.-PARMIANI G.
The italian network for tumor biotherapy (NIBIT): getting together to push the
field forward.
J. Transl. Med. 6:8;1/8;8, 2008
PubMed Abstract
MENARD S.-BALSARI A.-TAGLIABUE E.-CAMERINI T.-CASALINI P.-BUFALINO
R.-CASTIGLIONI F.-CARCANGIU M.-GLOGHINI A.-SCALONE S.-QUERZOLI P.-
LUNARDI M.-MOLINO A.-MANDARA' M.-MOTTOLESE M.-MARANDINO F.-
VENTURINI M.-BIGHIN C.-CANCELLO G.-MONTAGNA E.-PERRONE F.-DE
MATTEIS A.-SAPINO A.-DONADIO M.-BATTELLI N.-SANTINELLI A.-PAVESI
L.-LANZA A.-ZITO F.-LABRIOLA A.-AIELLO R.-CARUSO M.-ZANCONATI F.-
MUSTACCHI G.-BARBARESCHI M.-FRISINGHELLI M.-RUSSO R.-CARRILLO G.-
OMERO Group
Biology, prognosis and response to therapy of breast carcinomas
according to HER2 score.
Ann. Oncol. 19:1706/1712, 2008
PubMed Abstract
PASTORINO L.-BONELLI L.-GHIORZO P.-QUEIROLO P.-BATTISTUZZI L.-
BALLEARI E.-NASTI S.-GARGIULO S.-GLIORI S.-SAVOIA P.-ABATE S.-
BERNENGO M.-BIANCHI SCARRA' G.
CDKN2A mutations and MC1R variants in italian patients with single
or multiple primary melanoma.
Pigment Cell Melanoma Res. 21:700/709, 2008
PubMed Abstract
PRONZATO P.
New therapeutic options for chemotherapy resistant metastatic
breast cancer: the epothilones.
Drugs 68:139/146, 2008
PubMed Abstract
TISEO M.-ARDIZZONI A.-CAFFERATA M.-LOPREVITE M.-CHIARAMONDIA M.-FILIBERTI R.-MARRONI P.-GROSSI F.-PAGANUZZI M.
Predictive and prognostic significance of neuron specific enolase
(NSE) in non small cell lung cancer.
Anticancer Res. 28:507/514, 2008
PubMed Abstract
VIALE G.-GIOBBIE HURDER A.-REGAN M.-COATES A.-MASTROPASQUA M.-
DELL'ORTO P.-MAIORANO E.-MACGROGAN G.-BRAYE S.-OHLSCHLEGEL C.-
NEVEN P.-OROSZ Z.-OLSZEWSKI W.-KNOX F.-THURLIMANN B.-PRICE K.-
CASTIGLIONE GERTSCH M.-GELBER R.-GUSTERSON B.-GOLDHIRSCH A.-Breast
International Group Trial 1/98-ROSSO R.-DEL MASTRO L.-BIGHIN C.
Prognostic and predictive value of centrally reviewed Ki/67
labeling index in postmenopausal women with endocrine responsive
breast cancer: results from Breast International Group Trial 1/98
comparing adjuvant tamoxifen with letrozole.
J. Clin. Oncol. 26:5569/5575, 2008
PubMed Abstract
CASCINU S.-LABIANCA R.-BARONE C.-SANTORO A.-CARNAGHI C.-CASSANO A.-BERETTA G.-CATALANO V.-BERTETTO O.-BARNI S.-FRONTINI L.-AITINI E.-
ROTA S.-TORRI V.-FLORIANI I.-Italian Group Study Digestive Tract Cancer-CHIARA S.
Adjuvant treatment of high risk, radically resected gastric cancer patients with 5/fluorouracil, leucovorin, cisplatin, and
epidoxorubicin in a randomized controlled trial.
J. Natl. Cancer Inst. 99:601/607, 2007
PubMed Abstract
CAZZANIGA M.-MUSTACCHI G.-PRONZATO P.-DE MATTEIS A.-DI COSTANZO F.-FLORIANI I.
Adjuvant treatment of early breast cancer: do the St Gallen
recommendations influence clinical practice? Results from the NORA
study.
Ann. Oncol. 18:1976/1980, 2007
PubMed Abstract
CAZZANIGA M.-DOGLIOTTI L.-CASCINU S.-BARNI S.-LABIANCA R.-CHIARA S.-CONTE P.-GASPARINI
G.-PASETTO L.-TORRI V.
Diagnosis, management and clinical outcome of bone metastases in breast cancer
patients: results from a prospective, multicenter study.
Oncology 71:374/381, 2007
PubMed Abstract
CLAVAREZZA M.-DEL MASTRO L.-PRONZATO P.-BRUZZI P.-VENTURINI M.
Re: acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony stimulating factors during breast cancer
adjuvant chemotherapy. Letter.
J. Natl. Cancer Inst. 99:1050/1051, 2007
DEL MASTRO L.-CLAVAREZZA M.-VENTURINI M.
Reducing the risk of distant metastases in breast cancer patients: role of
aromatase inhibitors.
Cancer Treat. Rev. 33:681/687, 2007
PubMed Abstract
DEL MASTRO L.-DOZIN B.-AITINI E.-CATZEDDU T.-BALDINI E.-CONTU A.-DURANDO A.-DANESE
S.-CAVAZZINI G.-CANAVESE G.-BRUZZI P.-PRONZATO P.-VENTURINI M.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer:
findings from two consecutive trials of Gruppo Oncologico Nord Ovest Mammella
Intergruppo (GONO/MIG) Group.
Ann. Oncol. 19:299/307, 2008 - Epub Oct 17, 2007
PubMed Abstract
FALCONE A.-RICCI S.-BRUNETTI I.-PFANNER E.-ALLEGRINI G.-BARBARA C.-CRINO' L.-BENEDETTI G.-EVANGELISTA W.-FANCHINI L.-CORTESI E.-
PICONE V.-VITELLO S.-CHIARA S.-GRANETTO C.-PORCILE G.-FIORETTO L.-ORLANDINI C.-ANDREUCCETTI M.-MASI G.
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional
fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
J. Clin. Oncol. 25:1670/1676, 2007
PubMed Abstract
GENNARI A.-SORMANI M.-PRONZATO P.-PUNTONI M.-COLOZZA M.-PFEFFER U.-BRUZZI P.
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:
a pooled analysis of randomized trials.
J. Natl. Cancer Inst. 100:14/20, 2008 - Epub Dec 25, 2007
PubMed Abstract
GRIDELLI C.-AAPRO M.-BARNI S.-BERETTA G.-COLUCCI G.-DANIELE B.-DEL MASTRO L.-DI MAIO M.-DE PETRIS L.-PERRONE F.-THATCHER N.-DE MARINIS F.
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Crit. Rev. Oncol. Hematol. 63:53/64, 2007
PubMed Abstract
GROSSI F.-AITA M.-FOLLADOR A.-DEFFERRARI C.-BRIANTI A.-SINACCIO G.-BELVEDERE O.
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non small cell lung cancer: a review of
the literature.
Oncologist 12:451/464, 2007
PubMed Abstract
LOPREVITE M.-TISEO M.-CHIARAMONDIA M.-CAPELLETTI M.-BOZZETTI C.-BORTESI B.-NALDI
N.-NIZZOLI R.-DADATI P.-KUNKL A.-ZENNARO D.- LAGRASTA C.-CAMPANINI N.-SPIRITELLI
E.-CAMISA R.-GROSSI F.-RINDI G.-FRANCIOSI V.-ARDIZZONI A.
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in
patients with advanced non small cell lung cancer.
Clin. Cancer Res. 13:6518/6526, 2007
PubMed Abstract
PONZANELLI A.-VIGO V.-MARCENARO M.-BACIGALUPO A.-GATTESCHI B.-RAVETTI J.-CORVO'
R.-BENASSO M.
Induction chemotherapy followed by alternating chemo radiotherapy in non
endemic undifferentiated carcinoma of the nasopharynx:
optimal compliance and promising 4 year results.
Oral Oncol. Epub Nov 29, 2007
PubMed Abstract
QUEIROLO P.-ACQUATI M.
Medical treatment of uveal melanoma.
Tumori 93:27/30, 2007
SOLARI N.-ACQUATI M.-QUEIROLO P.-STELLA M.-DI SOMMA C.-TRUINI M.-CAFIERO F.
Primary melanoma of the esophagus with non metastatic dark lymph nodes in a
female breast cancer patients.
Anticancer Res. 27:2849/2854, 2007
PubMed Abstract
SUTER T.-PROCTER M.-VAN VELDHUISEN D.-MUSCHOLL M.-BERGH J.-CARLOMAGNO C.-PERREN T.-PASSALACQUA R.-BIGHIN C.-KLIJN J.-AGEEV F.-HITRE E.-GROETZ J.-IWATA
H.-KNAP M.-GNANT M.-MUEHLBAUER S.-SPENCE A.-GELBER R.-PICCART GEBHART M.
Trastuzumab associated cardiac adverse effects in the herceptin adjuvant trial.
J. Clin. Oncol. 25:3859/3865, 2007
PubMed Abstract
ARDIZZONI A.-CAFFERATA M.-TISEO M.-FILIBERTI R.-MARRONI P.-GROSSI F.-PAGANUZZI M.
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Cancer 107:2842/2849, 2006
PubMed Abstract
BAJETTA E.-DEL VECCHIO M.-NOVA P.-FUSI A.-DAPONTE A.-SERTOLI M.R.-QUEIROLO P.-TAVEGGIA P.-BERNENGO M.-LEGHA S.-
FORMISANO B.-CASCINELLI N.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous
interleukin/2 and interferon alpha2b in metastatic melanoma.
Ann. Oncol. 17:571/577, 2006
PubMed Abstract
BENASSO M.-PONZANELLI A.-MERLANO M.-NUMICO G.-RICCI I.-VIGO V.-GROSSI F.-AMADORI D.-CAVALLO G.-CAPACCETTI B.-TAVEGGIA P.-BONI L.-ROSSO R.
Paclitaxel, cisplatin and 5/fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an italian cooperative group.
Acta Oncol. 45:168/174, 2006
PubMed Abstract
CLAVAREZZA M.-DEL MASTRO L.-VENTURINI M.
Taxane containing chemotherapy in the treatment of early breast cancer patients.
Ann. Oncol. 17(suppl):vii22/vii26, 2006
PubMed Abstract
DE PAOLI A.-CHIARA S.-LUPPI G.-FRISO M.-BERETTA G.-DEL PRETE S.-PASETTO L.-SANTANTONIO M.-SARTI E.-MANTELLO G.-INNOCENTE R.-
FRUSTACI S.-CORVO' R.-ROSSO R.
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.
Ann. Oncol. 17:246/251, 2006
PubMed Abstract
DEL MASTRO L.-CATZEDDU T.-BONI L.-BELL C.-SERTOLI M.R.-BIGHIN C.-CLAVAREZZA M.-TESTA D.-VENTURINI M.
Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in
young, early breast cancer patients.
Ann. Oncol. 17:74/78, 2006
PubMed Abstract
DEL MASTRO L.-CATZEDDU T.-VENTURINI M.
Infertility and pregnancy after breast cancer: current knowledge and future perspectives.
Cancer Treat. Rev. 32:417/422, 2006
PubMed Abstract
GHIORZO P.-GARGIULO S.-PASTORINO L.-NASTI S.-CUSANO R.-BRUNO W.-GLIORI S.-SERTOLI M.R.-BURRONI A.-SAVARINO V.-GENSINI F.-SESTINI R.-QUEIROLO P.-GOLDSTEIN A.-BIANCHI SCARRA' G.
Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in italian melanoma families displaying pancreatic cancer and neuroblastoma.
Hum. Mol. Genet.15:2682/2689, 2006
PubMed Abstract
GROSSI F.-TISEO M.
Granulocyte growth factors in the treatment of non small cell lung cancer (NSCLC).
Crit. Rev. Oncol. Hematol. 58:221/230, 2006
PubMed Abstract
QUEIROLO P.-ACQUATI M.
Targeted therapies in melanoma.
Cancer Treat. Rev. 32:524/531, 2006
PubMed Abstract
RINALDI M.-BELVEDERE O.-CAUCHI C.-DEFFERRARI C.-VIOLA G.-GROSSI F.
Maintenance chemotherapy in non small cell lung cancer.
Ann. Oncol. 17(suppl):ii67/ii70, 2006
PubMed Abstract
SCALA M.-GIPPONI M.-QUEIROLO P.-MEREU P.-SOLARI N.-MONTEGHIRFO S.-CAFIERO F.
Cryosurgery for advanced malignant melanoma of the facial skin. A case report.
In Vivo 20:153/156, 2006
PubMed Abstract
TISEO M.-FRANCIOSI V.-GROSSI F.-ARDIZZONI A.
Adjuvant chemotherapy for non small cell lung cancer: ready for clinical practice?
Eur. J. Cancer 42:8/16, 2006
PubMed Abstract
TOMASELLO L.-GARDIN G.-BOCCARDO F.
Secondary breast angiosarcoma: lethal response to anti angiogenic therapy with paclitaxel chemotherapy. A case report.
Anticancer Res. 26:4775/4778, 2006
PubMed Abstract
VENTURINI M.-BIGHIN C.-MONFARDINI S.-CAPPUZZO F.-OLMEO N.-DURANDO A.-PUGLISI F.-NICOLETTO O.-LAMBIASE A.-DEL MASTRO L.
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first line treatment for HER2
overexpressing metastatic breast cancer.
Breast Cancer Res. Treat. 95:45/53, 2006
PubMed Abstract
Per le pubblicazioni 2000-2005 del personale della struttura vedere gli
elenchi generali.
|
Presentazione della struttura